Skip to main content

Table 1 Human tissue samples used in this study

From: The amyloid plaque proteome in early onset Alzheimer’s disease and Down syndrome

Patient ID Sex Age at death APOE genotype on FFPE or FT ABC score Fixation duration in weeks Inclusion in proteomics study Inclusion in IHC studies Number of plaques micro-dissected Number of non-plaques micro-dissected
EOAD #1 F 55 ɛ3/ɛ3; FFPE A3, B3, C3 2 Yes Yes 641 643
EOAD #2 M 62 ɛ3/ɛ3; FT A3, B3, C3 3 Yes Yes 622 622
EOAD #3 M 63 ɛ3/ɛ3; FFPE A3, B3, C3 2 Yes Yes 644 648
EOAD #4 M 63 ɛ4/ɛ4; FT A3, B3, C3 3 Yes Yes 627 627
EOAD #5 F 60 ɛ3/ɛ4; FT A3, B3, C3 3 Yes Yes 680 680
EOAD #6 M 70 ɛ3/ɛ3; FFPE A3, B3, C3 2   Yes n/a n/a
EOAD #7 F 70 ɛ3/ɛ3; FFPE A3, B3, C3 2   Yes n/a n/a
DS #1 F 58 ɛ3/ɛ3; FFPE A3, B3, C3 2 Yes Yes 607 607
DS #2 M 55 ɛ3/ɛ4; FFPE A3, B3, C3 2 Yes Yes 641 641
DS #3 M 54 ɛ3/ɛ3; FFPE A3, B3, C3 2 Yes Yes 603 603
DS #4 F 59 ɛ3/ɛ3; FFPE A3, B3, C3 2 Yes Yes 633 633
DS #5 F 37 ɛ3/ɛ3; FFPE A3, B3, C3 2 Yes Yes 626 624
LOAD #1 M 76 ɛ3/ɛ4; FT A3, B3, C3 3   Yes n/a n/a
LOAD #2 M 77 ɛ3/ɛ3; FFPE A3, B3, C3 3   Yes n/a n/a
LOAD #3 F 88 ɛ3/ɛ4; FT A3, B3, C3 2   Yes n/a n/a
Control #1 M 59 ɛ3/ɛ3; FFPE A1, B1, C0 3   Yes n/a n/a
Control #2 F 77 ɛ3/ɛ3; FFPE A1, B1, C1 2   Yes n/a n/a
Control #3 F 71 ɛ3/ɛ3; FFPE A1, B1, C0 2   Yes n/a n/a